Other Events ·
Filana Therapeutics received notice from Nasdaq on September 17, 2026, that its common stock failed to maintain the…
FLNAFilana Therapeutics, Inc.
Filana Therapeutics received notice from Nasdaq on September 17, 2026, that its common stock failed to maintain the $1.00 minimum bid price requirement for thirty consecutive business days. The company has until March 16, 2027, to regain compliance by maintaining a closing price of at least $1.00 for ten consecutive trading days. Failure to comply may result in delisting from the Nasdaq Capital Market. Filana Therapeutics operates as a clinical-stage biopharmaceutical company focused on developing therapies for rare diseases.